良性前列腺增生BPH.pdfVIP

复旦大学附属华山医院 姜昊文 • 2013AUA会议92个专题，摘要2319篇 • 与BPH相关的摘要有106篇 3 Podium sessions 4 Moderate poster sessions High levels of evidence : 7RCTs, 1 meta-analysis • Medical and hormonal therapy • Epidemiology and natural history /evaluation and markers • Basic research • Surgical therapy and new technology α Blocker 5ARI PDE5 Inhibitors Antimuscarinics • Finasteride+Tadalafil 针对BPH下尿路梗阻和勃起功能 • Alfuzosin +propiverine 对膀胱出口梗阻和膀胱过度活跃 • Tamsulosin+imidafenacin 针对BPH+OAB • Antimuscurinics +/- Alpha blockers 与尿潴留 • β3受体激动剂 Mirabegron • TUR的切除体积与术后的持续用药相关。 • Α blockers和5 α-R inhibitors 对伴随高血压的BPH • 度他雄胺 （REDUCE）的安全性和疗效 • Diazepam AADD 治疗夜尿 • 睾酮补充与下尿路症状 Effects of Tadalafil(TAD)and Finasteride(FIN) Co-Administration on LUTS and Erectile Function in Men with Prostatic Enlargement Secondary to BPH: 6-month, International, Randomized, Double-Blind, Parallel-Design Study • Provides early improvement in LUTS in men with moderate sized prostate volumes compared to finasteride alone- will need follow up to determine whether attenuated • Improved erectile function in men with and without baseline ED • Preservation of global sexual function(ie libido, ejaculation) • Safe, few adverse events RCT comparing alfuzosin with or without propiverene 10mg, 20mg, in men with symptomatic BPO and OAB; Cho H, Shin S, Seo DY, Cho J M, Kang JY, Yoo T K, Yu, J H, Sung LH, Moon HS Alfuzosin 10 mg 4,8 weeks: 150 Men: OABSS 40 yrs Alfuzosin 10mg+Propiverene 10mg IPSS IPSS: 8 or more